Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1155

Similar articles for PubMed (Select 19361748)

1.

Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications.

Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ.

Biol Blood Marrow Transplant. 2009 May;15(5):564-73. doi: 10.1016/j.bbmt.2009.01.011. Epub 2009 Mar 9.

3.

Costs of pediatric allogeneic hematopoietic-cell transplantation.

Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, Weisdorf DJ.

Pediatr Blood Cancer. 2010 Jan;54(1):138-43. doi: 10.1002/pbc.22250.

4.

Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.

Majhail NS, Brunstein CG, Tomblyn M, Thomas AJ, Miller JS, Arora M, Kaufman DS, Burns LJ, Slungaard A, McGlave PB, Wagner JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2008 Mar;14(3):282-9. doi: 10.1016/j.bbmt.2007.12.488.

5.

Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: impact of donor source on survival.

Kumar P, Defor TE, Brunstein C, Barker JN, Wagner JE, Weisdorf DJ, Burns LJ.

Biol Blood Marrow Transplant. 2008 Dec;14(12):1394-400. doi: 10.1016/j.bbmt.2008.09.021.

6.

Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.

Warlick ED, Cioc A, Defor T, Dolan M, Weisdorf D.

Biol Blood Marrow Transplant. 2009 Jan;15(1):30-8. doi: 10.1016/j.bbmt.2008.10.012.

7.

Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants.

Majhail NS, Brunstein CG, McAvoy S, DeFor TE, Al-Hazzouri A, Setubal D, Arora M, Le CT, Wagner JE, Weisdorf DJ.

Biol Blood Marrow Transplant. 2008 Sep;14(9):985-92. doi: 10.1016/j.bbmt.2008.06.008.

8.

Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.

Solh M, Brunstein C, Morgan S, Weisdorf D.

Biol Blood Marrow Transplant. 2011 May;17(5):710-6. doi: 10.1016/j.bbmt.2010.08.017. Epub 2010 Oct 14.

9.

Umbilical cord blood transplantation in adults using myeloablative and nonmyeloablative preparative regimens.

Koh LP, Chao NJ.

Biol Blood Marrow Transplant. 2004 Jan;10(1):1-22. Review.

PMID:
14752775
10.

[Umbilical cord blood cell transplantation from an unrelated donor: dual transplantation].

Bautista G, Regidor C, Gonzalo-Daganzo R, Cabrera JR.

Methods Find Exp Clin Pharmacol. 2010 Dec;32 Suppl A:47-51. Spanish.

PMID:
21381288
11.

Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB).

Arora M, Nagaraj S, Wagner JE, Barker JN, Brunstein CG, Burns LJ, Defor TE, McMillan ML, Miller JS, Weisdorf DJ.

Biol Blood Marrow Transplant. 2007 Oct;13(10):1145-52. Epub 2007 Jul 27.

12.
13.

The evolution of hematopoietic SCT in myelodysplastic syndrome.

Kindwall-Keller T, Isola LM.

Bone Marrow Transplant. 2009 Apr;43(8):597-609. doi: 10.1038/bmt.2009.28. Epub 2009 Mar 2. Review.

PMID:
19252532
14.

Kinetics of myeloid and lymphocyte recovery and infectious complications after unrelated umbilical cord blood versus HLA-matched unrelated donor allogeneic transplantation in adults.

Hamza NS, Lisgaris M, Yadavalli G, Nadeau L, Fox R, Fu P, Lazarus HM, Koc ON, Salata RA, Laughlin MJ.

Br J Haematol. 2004 Feb;124(4):488-98.

PMID:
14984500
15.

Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome.

Tomblyn MB, Arora M, Baker KS, Blazar BR, Brunstein CG, Burns LJ, DeFor TE, Dusenbery KE, Kaufman DS, Kersey JH, MacMillan ML, McGlave PB, Miller JS, Orchard PJ, Slungaard A, Tomblyn MR, Vercellotti GM, Verneris MR, Wagner JE, Weisdorf DJ.

J Clin Oncol. 2009 Aug 1;27(22):3634-41. doi: 10.1200/JCO.2008.20.2960. Epub 2009 Jul 6.

16.

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, Lee SJ, Windawi S, Ritz J, Stone RM, Antin JH, Soiffer RJ.

Blood. 2005 Feb 15;105(4):1810-4. Epub 2004 Sep 30.

17.

Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity.

Johnston L.

Best Pract Res Clin Haematol. 2008 Jun;21(2):177-92. doi: 10.1016/j.beha.2008.02.006. Review.

PMID:
18503985
18.

Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.

Al-Hazzouri A, Cao Q, Burns LJ, Weisdorf DJ, Majhail NS.

Biol Blood Marrow Transplant. 2008 Jun;14(6):658-63. doi: 10.1016/j.bbmt.2008.03.008.

19.

Outcomes of unrelated cord blood transplants and allogeneic-related hematopoietic stem cell transplants in children with high-risk acute lymphocytic leukemia.

Jacobsohn DA, Hewlett B, Ranalli M, Seshadri R, Duerst R, Kletzel M.

Bone Marrow Transplant. 2004 Nov;34(10):901-7.

PMID:
15361908
20.

[Umbilical cord blood as a source of stem cells].

Bojanić I, Golubić Cepulić B.

Acta Med Croatica. 2006 Jun;60(3):215-25. Review. Croatian.

PMID:
16933834
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk